Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis

Table 1

Baseline characteristics.

Study (ref.)	Sample size ()	Man/woman	Age (years) () (T/C)			Outcomes
Huang 2018 [14]	42/41	27/14		Febuxostat	Placebo	①③④⑤
Sircar 2015 [15]	45/48	66/27		Febuxostat	Placebo	②⑤
Zhang 2021 (1) [16]	36/30	41/25		Febuxostat	Placebo	①②③④⑤
Zhao 2021 [17]	41/41	47/35		Febuxostat	Placebo	①③④⑤
Sezai 2015 [18]	56/53	85/24		Febuxostat	Allopurinol	②
Tanaka 2015 [19]	21/19	35/5		Febuxostat	Allopurinol	②
Zhang 2021 (2) [20]	27/27	31/23		Febuxostat	Allopurinol	①③④⑤
Zhu 2018 [21]	32/32	NA	NA	Febuxostat	Allopurinol	①③④⑤
Zhang 2021 (3) [22]	67/67	66/68		Febuxostat	Allopurinol	①②③④⑤
Wang 2022 [23]	69/69	96/42		Febuxostat	Allopurinol	①②④⑤

①: serum uric acid; ②: EGFR; ③: serum creatinine; ④: serum urea nitrogen; ⑤: adverse reactions.